NEU Share Price

Open 0.06 Change Price %
High 0.06 1 Day 0.00 0.00
Low 0.06 1 Week 0.00 0.00
Close 0.06 1 Month 0.01 20.00
Volume 370119 1 Year -0.04 -40.00
52 Week High 0.13
52 Week Low 0.04
NEU Important Levels
Resistance 2 0.06
Resistance 1 0.06
Pivot 0.06
Support 1 0.06
Support 2 0.06
ASX Australia Most Active Stocks
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
AKK 0.01 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
IMU 0.02 100.00%
IMU 0.02 100.00%
PMQ 0.03 50.00%
ARD 0.03 50.00%
ARD 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
EXG 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
AVD 0.01 -50.00%
AVD 0.01 -50.00%
AVD 0.01 -50.00%
SRX 16.00 -37.23%
SRX 16.00 -37.23%
More..

Neuren Pharmaceuticals Ltd (ASX: NEU)

NEU Technical Analysis 1.5
As on 9th Dec 2016 NEU Share Price closed @ 0.06 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.08 & Buy for SHORT-TERM with Stoploss of 0.05 we also expect STOCK to react on Following IMPORTANT LEVELS.
NEU Target for December
1st Target up-side 0.08
2nd Target up-side 0.09
3rd Target up-side 0.1
1st Target down-side 0.04
2nd Target down-side 0.03
3rd Target down-side 0.02
NEU Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.neurenpharma.com
NEU Address
NEU
697 Burke Road
Suite 201
Camberwell, VIC 3124
Australia
Phone: 61 3 9092 0480
NEU Latest News
Interactive Technical Analysis Chart Neuren Pharmaceuticals Ltd ( NEU ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Neuren Pharmaceuticals Ltd
NEU Business Profile
Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders primarily in the United States. Its product development pipeline includes NNZ-2566 that is in Phase II clinical trials in rett syndrome, fragile X syndrome, and moderate to severe traumatic brain injury, as well as in concussion; and NNZ-2591, which is in preclinical development for chronic neurodegenerative conditions. The company has collaborative relationship with the US Army Medical Research & Materiel Command; and the Walter Reed Army Institute of Research. Neuren Pharmaceuticals Limited is based in Camberwell, Australia.